|Bid||1.3200 x 334700|
|Ask||1.3250 x 1317400|
|Day's range||1.3000 - 1.3650|
|52-week range||1.1300 - 2.5200|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Mar 1988|
|1y target est||N/A|
DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for pre-treatment with steroids nor G-CSF to reduce the risk of severe bone marrow toxicity.
Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection. Viraleze administered nasally reduced viral load by more than 99.9% in the lungs and trachea of animals challenged with the SARS-CoV-2 virus, compared to saline-control.
Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.